跳至主要内容
临床试验/EUCTR2009-015719-42-DK
EUCTR2009-015719-42-DK进行中(未招募)不适用

A 12-week, randomised, double-blind, placebo controlled trial to evaluate the efficacy, quality of life, safety and tolerability of prucalopride in male subjects with chronic constipation

Shire-Movetis NV0 个研究点目标入组 348 人开始时间: 2011年6月20日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
348

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Main inclusion criteria to be assessed at screening:
  • 1. Subject is a male out-patient =18 years of age (no upper age limit).
  • 2. Subject has a history of constipation, i.e. reports an average of =2
  • spontaneous bowel movements (SBM)/week that result in a feeling of
  • complete evacuation (SCBM) and one or more of the following for at
  • least 6 months before the selection visit:
  • a) Very hard (little balls) and/or hard stools for at least a quarter of the
  • b) Sensation of incomplete evacuation following for at least a quarter of
  • c) Straining at defecation for at least a quarter of the time.
  • The above criteria are only applicable for SBMs, i.e. BMs not preceded
  • within a period of 24 hours by the intake of a laxative agent or by the
  • use of an enema. Subjects who never have SBMs are considered to be
  • constipated and are eligible for the trial.
  • 3. Subject agrees to stop his current laxative treatment and is willing to
  • use rescue.
  • Main inclusion criteria to be assessed at baseline (randomisation):
  • 1. During the run-in period, the subject reports an average of =2
  • SBM/week that result in a feeling of complete evacuation (SCBM).* This
  • includes subjects who never have SBMs.
  • 2. Subject stopped his/her laxative treatment and did not use rescue
  • mediation on more than 75% of days during the run-in period.*
  • medication according to the rescue rule [Dulcolax® (bisacodyl)/
  • 3. Subject did not use disallowed medication during the run-in period.
  • * Excluding the first 7 days for subjects using medication influencing
  • bowel habit or excluding the days between screening and the 7 days
  • following the colonoscopy/sigmoidoscopy for those who had a
  • colonoscopy/sigmoidoscopy after screening.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Subjects in whom constipation is thought to be drug-induced.
  • 2. Subjects using any disallowed medication.
  • 3. Subjects suffering from secondary causes of chronic constipation.

研究者

发起方
Shire-Movetis NV

相似试验

进行中(未招募)
1 期
A study to evaluate the efficacy, quality of life, side effects and tolerability of long term treatment (12 weeks) with prucalopride in male patients aged =18 years with chronic constipatioMedDRA version: 14.1 Level: LLT Classification code 10063582 Term: Constipation chronic System Organ Class: 100000004856Chronic constipation
EUCTR2009-015719-42-GBShire-Movetis NV374
进行中(未招募)
1 期
A 12-week, randomised, double-blind, placebo controlled trial to evaluate the efficacy, quality of life, safety and tolerability of prucalopride in male subjects with chronic constipatioChronic constipation
EUCTR2009-015719-42-FRMovetis NV374
进行中(未招募)
不适用
A study to evaluate the efficacy, quality of life, side effects and tolerability of long term treatment (12 weeks) with prucalopride in male patients aged =18 years with chronic constipatioMedDRA version: 14.1Level: LLTClassification code 10063582Term: Constipation chronicSystem Organ Class: 100000004856Chronic constipation
EUCTR2009-015719-42-BGShire-Movetis NV348
进行中(未招募)
不适用
A study to evaluate the efficacy, quality of life, side effects and tolerability of long term treatment (12 weeks) with prucalopride in male patients aged =18 years with chronic constipatioChronic constipation
EUCTR2009-015719-42-CZShire-Movetis NV348
已完成
不适用
Sustained effects of resveratrol on circulatory function in obese adultsEndothelial vasodilator functionCognitive functionCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemMental Health - Studies of normal psychology, cognitive function and behaviour
ACTRN12611000060943Professor Peter Howe30